+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Inlyta (axitinib; Pfizer) Drug Overview 2019

  • ID: 4846106
  • Report
  • March 2019
  • Region: Global
  • 20 pages
  • Datamonitor Healthcare

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, and VEGFR-3. These receptors are believed to be implicated in angiogenesis, tumor growth, and metastasis.

Analyst Outlook
Inlyta was approved by the US Food and Drug Administration (FDA) in January 2012 for use in the treatment of patients with advanced renal cell cancer (RCC) after failure of one prior systemic therapy (Pfizer press release, 2012a). Inlyta subsequently received EU marketing authorization for the treatment of advanced RCC after failure of prior treatment with Sutent (sunitinib; Pfizer) or a cytokine (Pfizer press release, 2012b). These approvals were based on the results of a head-to-head Phase III trial with Nexavar (sorafenib; Bayer/Amgen), an established therapy in the second-line treatment of advanced RCC.
Note: Product cover images may vary from those shown
OVERVIEW
  • Drug Overview
  • Product Profiles
  • Inlyta: Renal cell carcinoma (RCC)
LIST OF FIGURES
Figure 1: Inlyta for RCC – SWOT analysis
Figure 2: The author's drug assessment summary of Inlyta for RCC
Figure 3: The author's drug assessment summary of Inlyta for RCC
Figure 4: Inlyta sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Inlyta drug profile
Table 2: Inlyta Phase III data in RCC
Table 3: Inlyta Phase III data in RCC
Table 4: Inlyta Phase III data in RCC
Table 5: Inlyta sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
Adroll
adroll